Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT

Agenus president Jennifer Buell talked to Scrip about partnering with Bristol and the dual nature approach of AGEN1777.

gold coins
Bristol agreed to pay $200m to Agenus • Source: Alamy

Cancer drug companies are racing to develop the next big immuno-oncology drugs, and Bristol Myers Squibb Company is doubling down on TIGIT in a new deal with Agenus Inc. The company paid $200m upfront for exclusive global rights to the bispecific antibody AGEN1777, a handsome price for a drug that is still in preclinical development.

Under the deal announced 18 May, Bristol also agreed to pay up to $1.36bn in development, regulatory and commercial milestones....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.